Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6807-6815

  Sagiv, Eyal ^a   Rozovski, Uri ^a   Kazanov, Diana ^a   Liberman, Eliezer ^a   Arber, Nadir ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2; JAGGED 2 PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PROSTAGLANDIN; PROTEIN LYSINE 6 OXIDASE; RAL PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; GENE CLUSTER; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC TRANSFECTION; GROWTH INHIBITION; INTESTINE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; UPREGULATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; ENTEROCYTES; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, RAS; HUMANS; PYRAZOLES; RATS; SULFONAMIDES;

EID: 36749082966     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1091     Document Type: Article

References (37)

1. Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for twenty-five sites in the adult population. Int JCancer 2002;97:72-81.
2. Ferlay J, Bray P, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2004.
3. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
4. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of Ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
5. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
6. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
7. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
8. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
9. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
10. Eberhart CE, DuBois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995;109:285-301.
11. Shiff SJ, Oiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
12. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996;12:893-901.
13. Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-6.
14. Duggan DE, Hooke KF, Hwang SS. Kinetics of the tissue distributions of sulindac and metabolites: relevance to sites and rates of bioactivation. Drug Metab Dispos 1980;8:241-6.
15. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
16. Hixson LJ, Alberts DS, Krutzsch M, et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994;3:433-8.
17. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-46.
18. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-812.
19. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, Nakamura Y. Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun 2002;292:498-512.
20. Hardwick JC, Van Santen M, van den Brink GR, van Deventer SJ, Peppelenbosch MP. DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis 2004;25:1293-8.
21. Harris N. C-K-ras transformed rat enterocytes (R1) are more sensitive than normal immortalized enterocytes (IEC18) to growth inhibition and apoptosis-induced by sulindac sulfone and nimesulid. Gastroenterology 1998;114:612A.
22. Kazanov D, Dvory-Sobol H, Pick M, et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 2004;10:267-71.
23. Arber N, Sutter T, Miyake M, et al. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene 1996;12:1903-8.
24. Arber N, Han EK, Sgambato A, et al. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology 1997;113:1892-900.
25. Won KA, Xiong Y, Beach D, Gilman MZ. Growth regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci U S A 1992;89:9910-4.
26. Sewing A, Burger C, Brusselbach S, Schalk C, Lucibello FC, Muller R. Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factor and suppressed by cyclic AMP. J Cell Sci 1993;104:545-54.
27. Kazanov D, Shapira I, Pick M, et al. Oncogenic transformation of normal enterocytes by overexpression of cyclin D1. Dig Dis Sci 2003;48:1251-61.
28. Arber N, Gammon MD, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 1999;30:1087-92.
29. Jiang W, Zhang YJ, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 1993;90:9026-30.
30. Kornmann M, Ishiwata T, Arber N, Beger HG, Korc M. Increased cyclin D1 expression in chronic pancreatitis. Pancreas 1998;17:158-62.
31. Arber N, Hibshoosh H, Yasui W, et al. Abnormalities in the expression of cell cycle related proteins in tumors of the small bowel. Cancer Epidemiol Biomarkers Prev 1999;12:1101-5.
32. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
33. 2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 2006;42:422-6.
34. Minn H, Joensu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumours. Cancer 1988;61:1776-81.
35. 18F]fluorodeoxyglucose and positron emission tomography. Eur J Cancer 1999;35:1773-82.
36. Yu Y, De Waele C, Chadee K. Calcium-dependent interleukin-8 gene expression in T84 human colonic epithelial cells. Inflamm Res 2001;50:220-6.
37. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58.